Scalper1 News
Biotech Pharmacyclics (PCYC) skyrocketed Tuesday after its preliminary Q4 sales and 2015 guidance beat estimates late Monday. Speaking at the JPMorgan Healthcare Conference in San Francisco, company officials said that fourth-quarter product revenue was around $185 million, up 31% sequentially and $15 million to $20 million above consensus estimates, according to RBC Capital Markets. The firm also took in $100 million in milestone payments from Scalper1 News
Scalper1 News